 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > TRANSGENE S.A.
 |
TRANSGENE S.A. |
 |
 |
 |
PROFILE |
 |
TRANSGENE's expertise in gene therapy may help it transform into a cancer fighter. The biotech company is focusing its R&D efforts on its two most promising cancer vaccine candidates. One of the products uses two antigens from the Human Papilloma Virus to treat cervical cancer, while the other candidate targets breast, lung, prostate, lung, and other cancers. In addition to these two projects, TRANSGENE is developing two immune therapy adjuvants that are injected directly into tumors, as well as other cancer immunotherapy products. The firm is seeking partners to take over development of its muscular dystrophy and cardiovascular gene therapy candidates. bioMérieux-Pierre Fabre owns more than half of TRANSGENE.
COMPETITION |
 |
Cell Genesys, Inc. (CEGE)
GenStar Therapeutics Corporation (GNT)
Targeted Genetics Corporation (TGEN)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 55.00
1-Yr. Sales Growth: 1,150.0%
KEY PEOPLE |
 |
Gilles Bélanger
CEO
Paul Bikard
CFO
CONTACT INFO |
 |
11, rue de Molsheim
67082 Strasbourg Cedex, France
Phone: 33-3-88-27-91-21
Fax: 33-3-88-27-91-11
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |